BIOCYTOGEN
20.2.2024 15:01:33 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access to Biocytogen’s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibodies for worldwide therapeutic development.
Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead’s evaluation of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive option exercise fees along with development, regulatory and sales milestone payments for each selected antibody against the nominated targets, as well as single-digit royalties on net sales.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are thrilled to collaborate with Gilead, a partner renowned for their drug development and commercialization expertise. Our extensive library of RenMice®-derived, fully human antibodies could serve as an important resource for Gilead to accelerate development of multiple novel antibody-based therapeutics to treat a variety of diseases. We are committed to supporting Gilead as well as our other partners in their drug development endeavors to benefit patients.”
About Biocytogen’s Fully Human Antibody Library
Biocytogen’s antibody library was generated using a series of proprietary RenMice® platforms, which were genetically engineered to accelerate the development of novel antibody-based therapeutics. RenMabTM mice carry the entire human antibody variable region repertoire, and can generate fully human antibodies with high diversity, low immunogenicity, outstanding specificity and affinity, and exhibit excellent developability properties. Second-generation RenLite® and RenNano® models, which generate common light chain antibodies and heavy-chain-only antibodies, respectively, further facilitate generation of fully human multi-specific antibodies or nanobodies. RenMice have also been engineered to lack specific drug targets; these targeted knockout platforms can generate antibodies with enhanced sequence and epitope diversity. This platform increases the likelihood of discovering novel species cross-reactive antibodies to facilitate downstream in vivo screening and identification of differentiated antibody candidates. A library featuring available antibody sequences along with characterization data is ready for immediate evaluation and partnership opportunities.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220445787/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only28.1.2026 07:07:00 CET | Press release
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human cerebrospinal fluid (CSF) within just 35 minutes. Alzheimer’s disease (AD) is characterized by the accumulation of neurofibrillary tangles in the brain, composed of hyperphosphorylated tau, and amyloid plaques, consisting of distinct β-amyloid peptides. CSF pTau217 has emerged as an early biomarker for neuropathological changes associated with AD. This new immunoassay further strengthens Fujirebio’s growing portfolio of neurological biomarkers and reinforces the company’s leading position in the advancement of associated research tools and diagnostics. “By adding pTau 217 CSF to our neuro portfol
NTT, DOCOMO, and NTT DATA to Exhibit at MWC Barcelona 202628.1.2026 07:00:00 CET | Press release
The NTT Group, comprising NTT, Inc., NTT DOCOMO, INC., and NTT DATA Group Corporation, announced today that they will jointly exhibit at MWC Barcelona 2026, the world’s largest connectivity event, to be held in Barcelona, Spain, from March 2 to March 5, 2026. At this event, the NTT Group will showcase its technological capabilities and foster deeper connections with leading global companies. Under the unified concept introduced following the corporate identity (CI) renewal on July 1, 2025, the NTT Group aims to strengthen its global brand presence and expand its business internationally. This will be the NTT Group’s first joint exhibition in seven years since 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127239513/en/ The NTT Group Booth at MWC Barcelona 2026 Under the theme, “Photonics Unlocks an Intelligent Power-Optimized Future,” the NTT Group will present its initiatives centered around IOWN1 optical technolog
Multi-Color Corporation Announces Recapitalization to Reset Balance Sheet and Position Company for Long-Term Growth and Investment27.1.2026 22:09:00 CET | Press release
MCC Enters into Restructuring Support Agreement to Eliminate Approximately $3.9 Billion of Outstanding Funded Debt, Reduce More than $330 Million of Cash Interest Expense in 2026 and Extend Long-Term Debt Maturities to 2033Restructuring Supported by CD&R and More Than Supermajority of Senior Secured Lenders Who Have Agreed to Backstop a Nearly $890 Million Investment; Provides More Than $500 Million of New Liquidity to Support Long-Term Growth and Investment Upon EmergenceLaunches Consent Solicitation and Expects to Implement Restructuring Through “Prepackaged” Chapter 11 Process; Restructuring Support Agreement Provides for CD&R to Be Controlling ShareholderAll Trade Vendors Expected to be Paid in Full; All Global Operations and Service to Customers Expected to Continue Without Interruption Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced strategic actions to further position the Company for long-term growth and investment to
Logitech Announces Q3 Fiscal Year 2026 Results27.1.2026 22:05:00 CET | Press release
Strong Financial Performance Driven By Strategic Priorities and Operational Discipline SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the third quarter of Fiscal Year 2026. Sales were $1.42 billion, up 6 percent in US dollars and 4 percent in constant currency compared to Q3 of the prior year. GAAP gross margin was 43.2 percent, up 30 basis points compared to Q3 of the prior year. Non-GAAP gross margin was 43.5 percent, up 30 basis points compared to Q3 of the prior year. GAAP operating income was $286 million, up 22 percent compared to Q3 of the prior year. Non-GAAP operating income was $312 million, up 17 percent compared to Q3 of the prior year. GAAP earnings per share (EPS) was $1.69, up 28 percent compared to Q3 of the prior year. Non-GAAP EPS was $1.93, up 21 percent compared to Q3 of the prior year. Cash flow from operations was $481 million. The quarter-ending cash balance w
Mobileum Launches GlobalRoamer® Connectivity Package for the FIFA World Cup 2026 to Assure Seamless Roaming and 5G Voice Performance Across North America27.1.2026 21:45:00 CET | Press release
Special event-ready active testing, monitoring, and benchmarking package provides daily reporting, venue-level insights, and proactive issue detection to protect roaming revenues and customer experience Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, today announced a Special GlobalRoamer® package for the FIFA World Cup 2026, designed to help mobile network operators (MNOs) validate roaming readiness and maintain high-quality connectivity during one of the world’s most demanding network events, where service performance directly impacts roaming revenue, customer retention, and brand reputation. The FIFA World Cup 2026 will place unprecedented pressure on mobile networks across 16 stadiums in the United States, Canada, and Mexico, as millions of fans, teams, media, and officials rely on mobile services to stream, share, and communicate in real time. Sudden spikes in data, voice, and roaming traffic can degrade performance precisely when customer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom